Recent Advances on Biomarkers of Sepsis-induced Acute Kidney Injury

Xiujuan Zang1 and Shougang Zhuang2

1Department of Nephrology, Songjiang Hospital Affiliated to the First People’s Hospital of Shanghai Jiaotong University, China
2Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, China
3Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, China

A R T I C L E I N F O

Article history:
Received: 14 November 2016
Accepted: 05 June 2017
Published: 14 June 2017

Keywords:
Biomarkers;
AKI;
Cystatin C;
NAGL

A B S T R A C T

SEPSIS is a complex clinical syndrome involving both infection and a deleterious host immune response. Acute Kidney Injury (AKI) is a frequent and serious complication of sepsis in Intensive Care Unit patient (ICU). Despite recent impressive advances in the pathophysiology, diagnostic procedures, and appropriate therapeutic interventions in sepsis, sepsis-induced AKI fails to reduce the overwhelmingly high mortality rate and longer hospital stay. A major obstacle for effective treatment of sepsis-induced AKI is the relative lack of specific early and effective diagnostic tools. Current clinical Serum Creatinine (Scr) is unable to detect the early AKI, in the past ten decades, studies have identified several biomarkers for the early diagnosis of AKI, but only limited information exists concerning their values in the diagnosis of sepsis-induced AKI. In this article, we have made a comprehensive review to discuss the clinical value of biomarkers in the diagnosis of sepsis-induced AKI.

Introduction

Sepsis, a complex clinical syndrome defined by the clinical response to a suspected or proven infection, is a leading cause of death worldwide. It is estimated that 18 million cases of sepsis occur each year in the world, with mortality rates ranging from 30% to 50% [1-3]. Sepsis affects persons of all ages [4], and is considered the 10th leading cause of death overall in the United States [5,6]. In the United States, approximately $24.3 billion is spent per year on the costs of hospitalization for septic patients [7]. AKI is very common in sepsis, and is associated with a higher risk of adverse outcomes [8]. AKI is a frequent and serious complication of sepsis in ICU patients [9], especially in the elderly [10]. Moreover, sepsis is the most important causes of AKI, accounting for 50% or more of cases of AKI in ICU, and associates with a very high mortality [11]. In adults, AKI occurs in approximately 19–23% of patients with moderate/severe sepsis, and in more than 50% in patients with septic shock [12]. The incidence of AKI increases with the severity of sepsis and estimates are that AKI develops within the first 24 hours in 64% of patients with severe sepsis and hypotension [13]. Strikingly, the mortality rate for septic patients with AKI is approximately doubled compared with sepsis alone [14]. Thus, early specific diagnostic tools, preclinical biomarkers, protecting the
Kidney could significantly reduce morbidity and mortality in patients with severe sepsis. The pathophysiology of sepsis-induced AKI is complex and multi-factorial, including intra-glomerular thrombosis, obstruction of tubules, infiltration of inflammatory cells, endothelial dysfunction and so on [15] (Figure 1).

There is an increasing evidence that sepsis-induced immune responses involve the activation of both pro- and anti-inflammatory mechanisms [16,17]. Inflammatory cascades and oxidative stress with microcirculatory changes play an important role in sepsis-induced AKI [18-21]. Important differences exist in Sepsis-induced AKI characteristics with a distinct pathophysiology between nonseptic origin patient [15,22-24] (Table 1). Firstly, both renal medullar and cortical blood flow is maintained and even increased during severe septic shock [15]. Secondly, there is an important role for apoptosis rather than necrosis in sepsis-induced renal tubular cell death [25,26]. Thirdly, both afferent and efferent arterioles are the same as dilatation, with greater efferent than afferent dilatation, leading to decreased capillary pressure and subsequent decrease in filtration and AKI [27]. In addition, a hyperemic injury is also thought to involve in the sepsis-induced AKI [28]. In recent years, it has been put forward that there is a continuum between transient AKI without tubular damage, transient AKI with minor tubular damage, and intrinsic AKI in sepsis. Thus, there may be a new subgroup of AKI, namely subclinical AKI, which was defined as a rise in biomarker level without a rise in Scr or a decrease in urinary output [29]. Accordingly, it is necessary to make a diagnosis of the subclinical sepsis-induced AKI by utilizing biomarkers. This review will focus on recent advances in biomarkers of sepsis-induced AKI and evaluation for their clinical value in the diagnosis of this disease.

**Sepsis-Induced Expression of AKI Biomarkers**

An ideal kidney function biomarker should be constantly produced, freely filtered, neither secreted nor reabsorbed by the renal tubule [30]. Unfortunately, a lot of kidney filtration biomarker is influenced by many extra-renal factors (muscle mass, age, gender, and reduced production in sepsis-AKI) and tubular secretion [31]. An ideal sepsis-induced AKI biomarkers should be an early detection biomarker that is tightly coupled to GFR, enabling rapid detection after the insult and identifying patients that may be at a higher risk, meanwhile a prognosis biomarker that can predict severity or mortality. There are partial early detection biomarkers of sepsis-induced AKI as following (Table 2).

1. **Cystatin C (CysC)**

CysC is a proteinase inhibitor that prevents connective tissue destruction [32], and its molecular weight is 13.3 kDa [33]. It is continuously produced by nucleated cells in the body, is filtered by the glomerulus, and then is entirely reabsorbed in the proximal tubule [34,35]. Serum CysC (sCysC) is affected by age, gender, muscle mass, smoking, thyroid function, and malignancies [36]. Whether sCysC is a better biomarker of AKI is still controversy [37,38]. Several studies have suggested...
that sCysC is an ideal endogenous biomarker of chronic kidney function [33,39-41].

<table>
<thead>
<tr>
<th>Table 1: The different pathophysiology of early AKI.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sepsis Non-sepsis</strong></td>
</tr>
<tr>
<td>Renal Blood Flow (RBF) increased RBF decreased RBF (hyperemic) (hypoperfusion)</td>
</tr>
<tr>
<td>Mechanism apoptosis and necrosis necrosis (inflammation, microvascular dysfunction, cellular energy regulation)</td>
</tr>
<tr>
<td>Manifests dramatic decline in GFR, tubular dysfunction variable tubular dysfunction.</td>
</tr>
</tbody>
</table>

NGAL, a 24-kDa protein consisting of 178 amino acid residues, is freely filtered by the glomerulus, and largely reabsorbed in the proximal tubules by efficient megalin-dependent endocytosis [52].The half-life of NGAL is estimated at 10–20 minutes [53]. It is postulated that increased serum and urinary NGAL are a sensitive marker of AKI, predominantly of damage to tubular cells, but do not reflect the decline of GFR. [54]. Several results showed that plasma NAGL might be able to detect not only AKI, but also sepsis [55,56]. Emerging evidence supports NGAL as a valuable biomarker of AKI and chronic kidney disease (CKD). Recently two trials initiated by Goldstein et al, and Ricci et al [57] showed that NGAL is a biomarker in predicting fluid accumulation and kidney injury in sepsis.

### Table 2: A partial biomarkers list of sepsis-induced AKI.

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Source of sample</th>
<th>Site of expression</th>
<th>Elevation in sepsis-induced AKI</th>
<th>Prognostic value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cystatin C</td>
<td>Plasma/urine</td>
<td>Nucleated cells</td>
<td>SCysC changed at 3h after CLP mice Urinary Cys predicts AKI 48-72h before Scr</td>
<td>Urinary CystainC</td>
</tr>
<tr>
<td>NAGL</td>
<td>Plasma/urine epithelial cells and neutrophils</td>
<td>Urinary NGAL 3 hours after injury peaking at 6 hours</td>
<td>Urinary NGAL</td>
<td></td>
</tr>
<tr>
<td>Neutrin-1</td>
<td>Urine PT, various organs</td>
<td>Urine 1 hour after injury peaking at 3-6 hours</td>
<td>NO</td>
<td></td>
</tr>
<tr>
<td>IL-18</td>
<td>Urine PT, renal cortex</td>
<td>12-18 hours after injury</td>
<td>predict the therapy, mortality</td>
<td></td>
</tr>
<tr>
<td>KIM-1</td>
<td>Urine PT</td>
<td>6 hours after injury peaking at 24 hours remained until 48 h</td>
<td>predict the severe level</td>
<td></td>
</tr>
<tr>
<td>sTREM-1</td>
<td>Urine monocytes, macrophages, and neutrophils</td>
<td>48 hours after injury</td>
<td>assess AKI severity</td>
<td></td>
</tr>
</tbody>
</table>

On the other hand, some studies have shown the superiority of sCysC as an early biomarker of AKI [42]. Urinary CysC predicts AKI 48-72h before Scr, while serum CysC may detect AKI one to two days earlier than Scr in Intensive Care Unit (ICU) patients who developed AKI [43]. Urinary CysC can be used for the diagnosis of kidney injury and sepsis, and predicts mortality in the intensive care unit [44]. SCysC also outperforms Scr as an early biomarker of AKI in the emergency patients [45], and in children after cardiopulmonary bypass [46].

Recently, a study by Asada et al [47] supposed that sCysC outperforms Scr and BUN as a renal function biomarker early in the course of sepsis-AKI. SCysC production is not largely affected by acute inflammation, including sepsis-induced inflammation, AKI [34,48,49]. SCysC is 3-fold higher than baseline while SCR is unchanged and BUN slightly changed at 3h after CLP mice. Thus, SCysC could meet the criterion of ideal biomarkers, SCysC is a better early detection biomarker than Scr in sepsis, and still influenced by non-renal factors that conspire to limit the accurate prediction of GFR during the evolution of sepsis-induced AKI.

2. Neutrophil gelatinase-associated lipocalin (NGAL)

NGAL is also known as lipid-transport protein 2 (lipocalin-2), one member of the lipocalin superfamily. It was initially found as an oncogene expressed by multiple human cells, including epithelial cells and neutrophils [50]. The major biological function of NGAL is its bacteriostatic feature related to iron-chelating properties [51].
paediatric AKI. Hur at al, demonstrated that plasma NGAL was a biomarker for AKI in critically ill patients with suspected sepsis, Cantaluppi et al, further showed that plasma NGAL was an early biomarker of DGF in kidney transplantation from extended criteria donors, Cruz DN provided that NGAL was a biomarker of cardiovascular disease beyond the kidneys, Damman et al. assumed NGAL as a biomarker in heart failure [58]. However, plasma NGAL can increase not only in sepsis - induced AKI, but during sepsis in the absence of AKI, this has been proved by Müge et al [59]. Plasma NGAL can be freely filtered by the glomerulus, and is largely reabsorbed in the proximal tubules by efficient megalin-dependent endocytosis [52]. It is possible that the pathophysiology of inflammatory response, with increased release of neutrophils, will have the effect on serum total NGAL concentration. Current results strongly pointed to NGAL as a marker of endothelial injury and neutrophil activation, rather than solely AKI, especially in sepsis - induced AKI patients [54]. All of these authors recently described increases in serum NGAL in septic patients without correlation to AKI [59-63]. Thus there is need to use other biomarkers in conjunction with both serum and urinary NGAL to accurately identify patients with both sepsis and AKI. Thus, Katagiri demonstrates that a biomarker panel consisting of plasma NGAL and EA assay can detect sepsis with high accuracy in AKI patients, both biomarkers can be evaluated in less than an hour from the time the patients enter the ICU, and significantly improved their detection performance incomplicated conditions of septic AKI [62].

3. Netrin-1

Netrin-1 is a laminin-like related family of axon guidance molecule. The netrins were discovered in the early 90s as neuronal guidance cues [66]. Netrin-1, initially described in central nervous system (CNS) during neurogenesis [67], is also expressed in various organs like intestine, pancreas, mammary glands, lung, kidney, blood vessels, etc. The major biological function of Netrin-1 is involved in angiogenesis, cell migration, tissue morphogenesis, tumor progression and growth, and regulation of inflammation. The kidney is one of organs expressing the highest levels of Netrin-1. It prominently locates in the interstitium in normal kidney, consistent with expression in peritubular capillaries [68]. Preclinical studies performed in murine models indicated that Netrin-1 is markedly induced in kidney tubule cells and excreted in the urine. It appears in the urine, as early as 1 hour after renal ischemic injury, increasing approximately 30-fold by 3 hours and peaking at 6 hours [69]. Recently, clinical study result shown that urinary netrin-1 levels increased significantly as early as 1h, peaked at 3-6 h and remained elevated up to 48 h of ICU admission in septic AKI patients [70], similar to its profiles in the preclinical studies Therefore, Netrin-1 may be a clinically useful biomarker in the early diagnosis of sepsis - induced AKI.

4. Interleukin-18 (IL-18) L-18

IL-18, a 22-kD proinflammatory cytokine, is expressed in the renal cortex, peritubular capillaries and interstitium [71]. IL-18 is translated as a procytokine subsequently cleaved by caspase-1 [72]. It promotes inflammation by signaling through the IL-18 receptor-
α/accessory protein–like heterodimer [73]. Urinary IL-18 has elevated within the first 6 hours after renal injury, but does not peak until after 12–18 hours, the excretion of IL-18 is higher in sepsis-induced AKI than in nonseptic AKI. IL-18 also predicted deterioration in kidney function, with increased values preceding clinically significant kidney failure by 24-48 h [74]. Recent studies have shown that urinary IL-18 levels can be used for the early diagnosis of AKI. Urine IL-18 levels also predict the mortality of patients who have ARDS and are in the intensive care unit [75].

5. Kidney injury molecule-1 (KIM-1)

KIM-1 is a 38.7-kD type 1 transmembrane glycoprotein that contains extracellular mucin and Ig domains [76]. Its expression is markedly up-regulated in proximal renal tubular cells in response to ischaemic or nephrotoxic AKI [77]. KIM-1 increased significantly by 6h, peaked at 24h and remained significantly elevated until 48h of ICU admission. These results suggest that KIM-1 is clinically useful as an early biomarker in the diagnosis of sepsis-induced AKI. In addition, persistent elevation of urinary KIM-1 level may be associated with poor prognosis [70].

6. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1)

sTREM-1, a 27-kD protein, can be excreted by the kidney. In the presence of kidney injury, a soluble form of TREM-1 can be released into body fluids. TREM-1 is a member of the immunoglobulin superfamily expressed mainly on mature monocytes, macrophages, and neutrophils [78]. Endothelial cells or the infiltrating inflammatory cells could produce sTREM-1, which measured in the urine, was able to predict the development of AKI. The AKI patients’ urine sTREM-1 levels at 48 h before diagnosis were significantly higher than those for the non-AKI patients [79]. If these results were to be confirmed by larger studies, urinary sTREM-1 would possibly become a new biomarker for sepsis-induced AKI.

Summary and Perspective

The ideal biomarker in sepsis-induced AKI would have several characteristics, including reliable detection of AKI; being sufficiently sensitive to detect early subclinical injury; reflecting the location of kidney injury; reflecting time dependent changes in the severity of injury; and being simple, cheap and easy to measure.

This review highlights the major studies that have characterized the diagnostic and prognostic predictive power of sepsis-induced AKI biomarkers. Serum and urine CysC, NGAL, urine Netrin-1 biomarkers can be used in the early diagnosis of sepsis-induced AKI. In addition, KIM-1 and IL-18, have function in prognostic predictive power.

Currently, the clinical use of novel AKI biomarkers is still unclear, and biomarker in sepsis-induced AKI is poorly studied. Since large, prospective, multicenter trials failed to show the value for early diagnosis of AKI using currently available biomarkers, it is necessary to further search for the ideal marker of sepsis-induced AKI has clearly not been completed yet.

Reference

27. Mussap M, Noto A, Fravega M, Fanos V. (2011). Urine neutrophil gelatinase-associated lipocalin (uNGAL) and netrin-1: are they effectively improving the clinical management of sepsis-induced acute kidney injury (AKI)? The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet 24 Suppl. 2: 15-17.
69. Reeves WB, Kwon O, Ramesh G. (2008). Netrin-1 and kidney injury. II. Netrin-1 is an early...